Page 2206 - Williams Hematology ( PDFDrive )

2180 Part XII: Hemostasis and Thrombosis Chapter 126: von Willebrand Disease 2181

262. Sadler JE: Von Willebrand disease type 1: A diagnosis in search of a disease. Blood 293. Flood VH, Gill JC, Friedman KD, et al: Collagen binding provides a sensitive screen for
101:2089–2093, 2003. variant von Willebrand disease. Clin Chem 59:684–691, 2013.
263. Lillicrap D: Von Willebrand disease: Advances in pathogenetic understanding, diagno- 294. Flood VH, Lederman CA, Wren JS, et al: Absent collagen binding in a VWF A3 domain
sis, and therapy. Blood 122:3735–3740, 2013. mutant: Utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost 8:1431–1433,
264. Weiss HJ, Ball AP, Mannucci PM: Incidence of severe von Willebrand’s disease. N Engl 2010.
J Med 307:127, 1982. 295. Flood VH, Gill JC, Christopherson PA, et al: Critical von Willebrand factor A1 domain
265. Berliner SA, Seligsohn U, Zivelin A, et al: A relatively high frequency of severe (type III) residues influence type VI collagen binding. J Thromb Haemost 10:1417–1424, 2012.
von Willebrand’s disease in Israel. Br J Haematol 62:535–543, 1986. 296. Favaloro EJ, Dean M, Grispo L, et al: Von Willebrand’s disease: Use of collagen bind-
266. Mannucci PM, Bloom AL, Larrieu MJ, et al: Atherosclerosis and von Willebrand fac- ing assay provides potential improvement to laboratory monitoring of desmopressin
tor. I. Prevalence of severe von Willebrand’s disease in western Europe and Israel. Br J (DDAVP) therapy. Am J Hematol 45:205–211, 1994.
Haematol 57:163–169, 1984. 297. Riddell AF, Jenkins PV, Nitu-Whalley IC, et al: Use of the collagen-binding assay for
267. Nosek-Cenkowska B, Cheang MS, Pizzi NJ, et al: Bleeding/bruising symptomatology in von Willebrand factor in the analysis of type 2M von Willebrand disease: A comparison
children with and without bleeding disorders. Thromb Haemost 65:237–241, 1991. with the ristocetin cofactor assay. Br J Haematol 116:187–192, 2002.
268. Rydz N, James PD: The evolution and value of bleeding assessment tools. J Thromb 298. Popov J, Zhukov O, Ruden S, et al: Performance and clinical utility of a commercial von
Haemost 10:2223–2229, 2012. Willebrand factor collagen binding assay for laboratory diagnosis of von Willebrand
269. Elbatarny M, Mollah S, Grabell J, et al: Normal range of bleeding scores for the ISTH- disease. Clin Chem 52:1965–1967, 2006.
BAT: Adult and pediatric data from the merging project. Haemophilia 20:831–835, 299. Meiring M, Badenhorst PN, Kelderman M: Performance and utility of a cost-effective
2014. collagen-binding assay for the laboratory diagnosis of Von Willebrand disease.
270. Federici AB, Bucciarelli P, Castaman G, et al: The bleeding score predicts clinical out- Clin Chem Lab Med 45:1068–1072, 2007.
comes and replacement therapy in adults with von Willebrand disease. Blood 123: 300. Mazurier C, Meyer D: Factor VIII binding assay of von Willebrand factor and the diag-
4037–4044, 2014. nosis of type 2N von Willebrand disease-results of an international survey. On behalf
271. van den Driesche S, Mummery CL, Westermann CJ: Hereditary hemorrhagic telang- of the Subcommittee on von Willebrand Factor of the Scientific and Standardization
iectasia: An update on transforming growth factor beta signaling in vasculogenesis and Committee of the ISTH. Thromb Haemost 76:270–274, 1996.
angiogenesis. Cardiovasc Res 58:20–31, 2003. 301. Zhukov O, Popov J, Ramos R, et al: Measurement of von Willebrand factor-FVIII bind-
272. Iannuzzi MC, Hidaka N, Boehnke ML, et al: Analysis of the relationship of von Wille- ing activity in patients with suspected von Willebrand disease type 2N: Application of
brand disease (vWD) and hereditary hemorrhagic telangiectasia and identification of a an ELISA-based assay in a reference laboratory. Haemophilia 15:788–796, 2009.
potential type IIA vWD mutation (IIe865 to Thr). Am J Hum Genet 48:757–763, 1991. 302. Casonato A, Pontara E, Sartorello F, et al: Identifying carriers of type 2N von Wille-
273. Rick ME, Williams SB, Sacher RA, McKeown LP: Thrombocytopenia associated with brand disease: Procedures and significance. Clin Appl Thromb Hemost 13:194–200,
pregnancy in a patient with type IIB von Willebrand’s disease. Blood 69:786–789, 1987. 2007.
274. Mazurier C, Parquet-Gernez A, Goudemand J, et al: Investigation of a large kindred 303. Haberichter SL, Balistreri M, Christopherson P, et al: Assay of the von Willebrand fac-
with type IIB von Willebrand’s disease, dominant inheritance and age-dependent tor (VWF) propeptide to identify patients with type 1 von Willebrand disease with
thrombocytopenia. Br J Haematol 69:499–505, 1988. decreased VWF survival. Blood 108:3344–3351, 2006.
275. Gupta M, Lillicrap D, Stain AM, et al: Therapeutic consequences for misdiagnosis of 304. Haberichter SL, Castaman G, Budde U, et al: Identification of type 1 von Willebrand
type 2N von Willebrand disease. Pediatr Blood Cancer 57:1081–1083, 2011. disease patients with reduced von Willebrand factor survival by assay of the VWF pro-
276. Schneppenheim R, Budde U, Krey S, et al: Results of a screening for von Willebrand peptide in the European study: Molecular and clinical markers for the diagnosis and
disease type 2N in patients with suspected haemophilia A or von Willebrand disease management of type 1 VWD (MCMDM-1VWD). Blood 111:4979–4985, 2008.
type 1. Thromb Haemost 76:598–602, 1996. 305. Casonato A, Pontara E, Sartorello F, et al: Identifying type Vicenza von Willebrand
277. James PD, Lillicrap D, Mannucci PM: Alloantibodies in von Willebrand disease. Blood disease. J Lab Clin Med 147:96–102, 2006.
122:636–640, 2013. 306. Fressinaud E, Veyradier A, Truchaud F, et al: Screening for von Willebrand disease with
278. Asatiani E, Kessler CM: Multiple congenital coagulopathies co-expressed with von a new analyzer using high shear stress: A study of 60 cases. Blood 91:1325–1331, 1998.
Willebrand’s disease: The experience of Hemophilia Region III Treatment Centers over 307. Cattaneo M, Federici AB, Lecchi A, et al: Evaluation of the PFA-100 system in the
25 years and review of the literature. Haemophilia 13:685–696, 2007. diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb
279. Lippi G, Franchini M, Poli G, et al: Is the activated partial thromboplastin time suitable Haemost 82:35–39, 1999.
to screen for von Willebrand factor deficiencies? Blood Coagul Fibrinolysis 18:361–364, 308. De Vleeschauwer A, Devreese K: Comparison of a new automated von Willebrand fac-
2007. tor activity assay with an aggregation von Willebrand ristocetin cofactor activity assay
280. Abildgaard CF, Suzuki Z, Harrison J, et al: Serial studies in von Willebrand’s disease: for the diagnosis of von Willebrand disease. Blood Coagul Fibrinolysis 17:353–358,
Variability versus “variants.” Blood 56:712–716, 1980. 2006.
281. Timm A, Fahrenkrug J, Jorgensen HL, et al: Diurnal variation of von Willebrand factor 309. Salem RO, Van Cott EM: A new automated screening assay for the diagnosis of von
in plasma: The Bispebjerg study of diurnal variations. Eur J Haematol 93:48–53, 2014. Willebrand disease. Am J Clin Pathol 127:730–735, 2007.
282. Sadler JE: Von Willebrand disease type 1: A diagnosis in search of a disease. Blood 310. Sucker C, Senft B, Scharf RE, Zotz RB: Determination of von Willebrand factor activ-
101:2089–2093, 2003. ity: Evaluation of the HaemosIL assay in comparison with established procedures. Clin
283. Sadler JE: New concepts in von Willebrand disease. Annu Rev Med 56:173–191, 2005. Appl Thromb Hemost 12:305–310, 2006.
284. Quiroga T, Goycoolea M, Belmont S, et al: Quantitative impact of using different cri- 311. Pinol M, Sales M, Costa M, et al: Evaluation of a new turbidimetric assay for von
teria for the laboratory diagnosis of type 1 von Willebrand disease. J Thromb Haemost Willebrand factor activity useful in the general screening of von Willebrand disease.
12:1238–1243, 2014. Haematologica 92:712–713, 2007.
285. Hayward CP, Moffat KA, Plumhoff E, Van Cott EM: Approaches to investigating com- 312. Fujimura Y, Kawasaki T, Titani K: Snake venom proteins modulating the interaction
mon bleeding disorders: An evaluation of North American coagulation laboratory between von Willebrand factor and platelet glycoprotein Ib. Thromb Haemost 76:633–
practices. Am J Hematol 87 Suppl 1:S45–S50, 2012. 639, 1996.
286. Favaloro EJ, Bonar R, Chapman K, et al: Differential sensitivity of von Willebrand factor 313. Keeney S, Bowen D, Cumming A, et al: The molecular analysis of von Willebrand
(VWF) “activity” assays to large and small VWF molecular weight forms: A cross-lab- disease: A guideline from the UK Haemophilia Centre Doctors’ Organisation Haemo-
oratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. J philia Genetics Laboratory Network. Haemophilia 14:1099–1111, 2008.
Thromb Haemost 10:1043–1054, 2012. 314. Snyder MW, Simmons LE, Kitzman JO, et al: Noninvasive fetal genome sequencing: A
287. Eikenboom J, Federici AB, Dirven RJ, et al: VWF propeptide and ratios between VWF, primer. Prenat Diagn 33:547–554, 2013.
VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. 315. James PD, Lillicrap D: The molecular characterization of von Willebrand disease: Good
Blood 121:2336–2339, 2013. in parts. Br J Haematol 161:166–176, 2013.
288. Weiss HJ, Hoyer LW, Rickles FR, et al: Quantitative assay of a plasma factor deficient in 316. Othman M, Kaur H, Emsley J: Platelet-type von Willebrand disease: New insights
von Willebrand’s disease that is necessary for platelet aggregation. J Clin Invest 52:2708– into the molecular pathophysiology of a unique platelet defect. Semin Thromb Hemost
2716, 1973. 39:663–673, 2013.
289. Rodeghiero F, Castaman G, Tosetto A: Von Willebrand factor antigen is less sensitive 317. Federici AB, Budde U, Castaman G, et al: Current diagnostic and therapeutic
than ristocetin cofactor for the diagnosis of type I von Willebrand disease-results based approaches to patients with acquired von Willebrand syndrome: A 2013 update. Semin
on an epidemiological investigation. Thromb Haemost 64:349–352, 1990. Thromb Hemost 39:191–201, 2013.
290. Favaloro EJ: Diagnosis and classification of von Willebrand disease: A review of the 318. Budde U, Schaefer G, Mueller N, et al: Acquired von Willebrand’s disease in the myelo-
differential utility of various functional von Willebrand factor assays. Blood Coagul proliferative syndrome. Blood 64:981–985, 1984.
Fibrinolysis 22:553–564, 2011. 319. Kos CA, Ward JE, Malek K, et al: Association of acquired von Willebrand syndrome
291. Ruggeri ZM, Zimmerman TS: The complex multimeric composition of factor VIII/von with AL amyloidosis. Am J Hematol 82:363–367, 2007.
Willebrand Factor. Blood 57:1140–1143, 1981. 320. Mannucci PM, Lombardi R, Bader R, et al: Studies of the pathophysiology of acquired
292. Budde U, Schneppenheim R, Eikenboom J, et al: Detailed von Willebrand factor multi- von Willebrand’s disease in seven patients with lymphoproliferative disorders or benign
mer analysis in patients with von Willebrand disease in the European study, molecular monoclonal gammopathies. Blood 64:614–621, 1984.
and clinical markers for the diagnosis and management of type 1 von Willebrand dis- 321. Rogers JS, Shane SR, Jencks FS: Factor VIII activity and thyroid function. Ann Intern
ease (MCMDM-1VWD). J Thromb Haemost 6:762–771, 2008. Med Intern Med 97:713–716, 1982.

Kaushansky_chapter 126_p2163-2182.indd 2181 9/21/15 3:15 PM